Expression of TSG101 protein and LSF transcription factor in HPV-positive cervical cancer cells

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1409-1413

  Broniarczyk, Justyna K ^a   Warowicka, Alicja ^a   Kwaśniewska, Anna ^b   Wohuń Cholewa, Maria ^c   Kwaśniewski, Wojciech ^d   Goździcka Józefiak, Anna ^c  

^a Department of Molecular Virology ^*  (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cervical cancer; LSF transcription factor; TSG101 protein

Indexed keywords

TRANSCRIPTION FACTOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; VIRUS DNA;

ADULT; ARTICLE; BIOINFORMATICS; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; SIMIAN VIRUS 40; UTERINE CERVIX CANCER; VIRUS DETECTION;

EID: 84896277275     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1967     Document Type: Article

References (50)

1. Broniarczyk J, Olejnik-Schmidt AK, Luczak MW, Schmidt MT, Dabrowski M, Józefiak A, Kedzia W, Kwaśniewska A and Goździcka-Józefiak A: Analysis of expression and structure of the TSG101 gene in cervical cancer cells. Int J Mol Med 25: 777-783, 2010.
2. Li L, Li X, Francke U and Cohen SN: The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 88: 143-154, 1997.
3. Singh RK, Dasgupta S, Bhattacharya N, Chunder N, Mondal R, Roy A, Mandal S, Roychowdhury S and Panda CK: Deletion in chromosome 11 and Bcl-1/Cyclin D1 alterations are independently associated with the development of uterine cervical carcinoma. J Cancer Res Clin Oncol 131: 395-406, 2005.
4. Carstens MJ, Krempler A, Triplett AA, Van Lohuizen M and Wagner KU: Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem 279: 35984-35994, 2004.
5. Koonin EV and Abagyan RA: TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet 16: 330-331, 1997.
6. Ponting CP, Cai YD and Bork P: The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med 75: 467-469, 1997.
7. Watanabe M, Yanagi Y, Masuhiro Y, Yano T, Yoshikawa H, Yanagisawa J and Kato S: A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 245: 900-905, 1998.
8. Hittelman AB, Burakov D, Iñiguez-Lluhí JA, Freedman LP and Garabedian MJ: Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 18: 5380-5388, 1999.
9. Babst M, Odorizzi G, Estepa EJ and Emr SD: Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 1: 248-258, 2000.
10. Garrus JE, von Schwedler UK, Pornillos OW, et al: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107: 55-65, 2001.
11. Lu Q, Hope LW, Brasch M, Reinhard C and Cohen SN: TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc Natl Acad Sci USA 100: 7626-7631, 2003.
12. Bache KG, Brech A, Mehlum A and Stenmark H: Hrs regulates multivesicular body formation via ESCRT recruitment to endosomes. J Cell Biol 162: 435-442, 2003.
13. Zhong Q, Chen Y, Jones D and Lee WH: Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 58: 2699-2702, 1998.
14. Xie W, Li L and Cohen SN: Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci USA 95: 1595-1600, 1998.
15. Ruland J, Sirard C, Elia A, MacPherson D, Wakeham A, Li L, de la Pompa JL, Cohen SN and Mak TW: p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc Natl Acad Sci USA 98: 1859-1864, 2001.
16. Krempler A, Henry MD, Triplett AA and Wagner KU: Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J Biol Chem 277: 43216-43223, 2002.
17. Wagner KU, Krempler A, Qi Y, Park K, Henry MD, Triplett AA, Riedlinger G, Rucker EB and Hennighausen L: Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23: 150-162, 2003.
18. Kim CH, Heath C, Bertuch A and Hansen U: Specific stimulation of simian virus 40 late transcription in vitro by a cellular factor binding the simian virus 40 21-base-pair repeat promoter element. Proc Natl Acad Sci USA 84: 6025-6029, 1987.
19. Swendeman SL, Spielholz C, Jenkins NA, Gilbert DJ, Copeland NG and Sheffery M: Characterization of the genomic structure, chromosomal location, promoter, and development expression of the alpha-globin transcription factor CP2. J Biol Chem 269: 11663-11671, 1994.
20. Cunningham JM, Vanin EF, Tran N, Valentine M and Jane SM: The human transcription factor CP2 (TFCP2), a component of the human gamma-globin stage selector protein, maps to chromosome region 12q13 and is within 250kb of the NF-E2 gene. Genomics 30: 398-399, 1995.
21. Venkatesan K, McManus HR, Mello CC, Smith TF and Hansen U: Functional conservation between members of an ancient duplicated transcription factor family, LSF/Grainyhead. Nucleic Acids Res 31: 4304-4316, 2003.
22. Wilanowski T, Tuckfield A, Cerruti L, O'Connell S, Saint R, Parekh V, Tao J, Cunningham JM and Jane SM: A highly conserved novel family of mammalian developmental transcription factors related to Drosophila grainyhead. Mech Dev 114: 37-50, 2002.
23. Traylor-Knowles N, Hansen U, Dubuc TQ, Martindale MQ, Kaufman L and Finnerty JR: The evolutionary diversification of LSF and Grainyhead transcription factors preceded the radiation of basal animal lineages. BMC Evol Biol 10: 10, 2010.
24. Santhekadur PK, Rajasekaran D, Siddiq A, Gredler R, Chen D, Schaus SE, Hansen U, Fisher PB and Sarkar D: The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. Am J Cancer Res 2: 269-285, 2012.
25. Shirra MK and Hansen U: LSF and NTF-1 share a conserved DNA recognition motif yet require different oligomerization states to form a stable protein-DNA complex. J Biol Chem 273: 19260-19268, 1998.
26. Kokoszynska K, Ostrowski J, Rychlewski L and Wyrwicz LS: The fold recognition of CP2 transcription factors gives new insights into the function and evolution of tumor suppressor protein p53. Cell Cycle 7: 2907-2915, 2008.
27. Drouin EE, Schrader CE, Stavnezer J and Hansen U: The ubiquitously expressed DNA-binding protein late SV40 factor binds Ig switch regions and represses class switching to IgA. J Immunol 168: 2847-2856, 2002.
28. Zambrano N, Minopoli G, de Candia P and Russo T: The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1. J Biol Chem 273: 20128-20133, 1998.
29. Hansen U, Owens L and Saxena UH: Transcription factors LSF and E2Fs: tandem cyclists driving G0 to S? Cell Cycle 8: 2146-2151, 2009.
30. Powell CM, Rudge TL, Zhu Q, Johnson LF and Hansen U: Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. EMBO J 19: 4665-4675, 2000.
31. Manos MM, Ting Y, Wright DK, et al: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7: 209-214, 1989.
32. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H and Iwamoto A: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. J Cancer Res 82: 524-531, 1991.
33. Daud II and Scott ME: Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol 15: 1369-1373, 2008.
34. Wagner KU, Dierisseau P, Rucker EB, Robinson GW and Hennighausen L: Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 17: 2761-2770, 1998.
35. Liu RT, Huang CC, You HL, Chou FF, Hu CC, Chao FP, Chen CM and Cheng JT: Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21: 4830-4837, 2002.
36. Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J and Cheng X: Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol Cell Proteomics 6: 294-304, 2007.
37. Kidd M, Nadler B, Mane S, Eick G, Malfertheiner M, Champaneria M, et al: GeneChip, geNorm and gastrointestinal tumors: novel reference genes for real-time PCR. Physiol Genomics 30: 363-370, 2007.
38. Swendeman SL, Spielholz C, Jenkins NA, Gilbert DJ, Copeland NG and Sheffery M: Characterization of the genomic structure, chromosomal location, promoter, and developmental expression of the B-globin transcription factor CP2. J Biol Chem 269: 11663-11671, 1994.
39. Ramamurthy L, Barbour V, Tuckfield A, Clouston DR, Topham D, Cunningham JM, et al: Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors. J Biol Chem 276: 7836-7842, 2001.
40. Saxena UH, Powell CMH, Fecko JK, Cacioppo R, Chou HS, Cooper GM and Hansen U: Phosphorylation by cyclin C/cyclin-dependent kinase 2 following mitogenic stimulation of murine fibroblasts inhibits transcriptional activity of LSF during G1 progression. Mol Cell Biol 29: 2335-2345, 2009.
41. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U and Margolis DM: The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74: 6790-6799, 2000.
42. Lace MJ, Yamakawa Y, Ushikai M, Anson JR, Hangen TH and Turek LP: Cellular factor YY1 downregulates the human papillomavirus 16 E6/E7 promoter, P97, in vivo and in vitro from a negative element overlapping the transcrition-initiation site. J Gen Virol 90: 2402-2412, 2009.
43. Fan R, Chen P, Zhao D, Tonq JL, Li J and Liu F: Cooperation of deregulated Notch signaling and Ras pathway in human hepatocarcinogenesis. J Mol Histol 42: 473-481, 2011.
44. Zagouras P, Stifani S, Blaumeller CM, Carcangiu ML and Artavanis-Tsakonas S: Alterations in Notch signaling in neoplastic lesions of human cervix. Proc Natl Acad Sci USA 92: 6414-6418, 1995.
45. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, Koontongkaew S, Liotta LA, Emmert-Buck M and Gutkind JS: Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by use of laser capture microdissection and cDNA arrays. Oncogene 19: 3220-3224, 2000.
46. Westhoff B., Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G, Viale G, Pece S and Di Fiore PP, Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA 106: 22293-22298, 2009.
47. Zhang Y, Li B, Ji ZZ and Zheng PS: Notch 1 regulates the growth of human colon cancer. Cancer 116: 5207-5218, 2010.
48. Okuhashi Y, Nara N and Tohoda S: Effects of gamma-secretase inhibitors on the growth of leukemia cells. Anticancer Res 30: 495-498, 2010.
49. Shlomai A: Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed? World J Gastroenterol 18: 6709-6711, 2012.
50. Veljkovic J and Hansen U: Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene 343: 23-40, 2004.